Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County.
Adult
Cross-Sectional Studies
Female
HIV Infections
/ epidemiology
Hepatitis B
/ epidemiology
Hepatitis B Surface Antigens
/ blood
Hepatitis C
/ epidemiology
Hepatitis C Antibodies
/ blood
Humans
Logistic Models
Male
Prevalence
Prisoners
RNA, Viral
/ analysis
Sweden
/ epidemiology
Vaccination
/ statistics & numerical data
HCV RNA
HIV
Hepatitis B
Hepatitis C
Prevalence
Prison
Screening
Vaccination
Viremic HCV infection
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
09 Nov 2019
09 Nov 2019
Historique:
received:
24
04
2019
accepted:
21
10
2019
entrez:
11
11
2019
pubmed:
11
11
2019
medline:
15
1
2020
Statut:
epublish
Résumé
Identification and knowledge of settings with high prevalence of hepatitis C virus (HCV) infection is important when aiming for elimination of HCV. The primary aim of this study was to estimate the prevalence of viremic HCV infection among Swedish prisoners. Secondary aims were to estimate the prevalence of hepatitis B surface antigen (HBsAg), human immunodeficiency virus (HIV), and the proportion who have received hepatitis B virus (HBV) vaccination. A cross-sectional study of all incarcerated persons (n = 667) at all prisons (n = 9) in Stockholm County was conducted. All prisoners are routinely offered opt-in screening for HCV antibodies (anti-HCV), HCV RNA, HBsAg, anti-HBs, anti-HBc and HIV Ag/Ab at prison in Sweden. Data on the results of these tests and the number of received HBV vaccine doses were collected from the prison medical records. The parameters of HCV RNA, anti-HCV, and occurrence of testing for HCV were analysed in multiple logistic regression models in relation to age, sex and prison security class. The median age was 35 (IQR 26-44) years, and 93.4% were men. Seventy-one percent (n = 471) had been tested for anti-HCV, 70% (n = 465) for HBsAg and 71% (n = 471) for HIV. The prevalence of anti-HCV, HCV RNA, HBsAg and HIV Ag/Ab was 17.0, 11.5, 1.9, and 0.2%, respectively among tested persons. The proportion of prisoners who had received full HBV vaccination was 40.6% (n = 271) among all study subjects. The prevalence of viremic HCV infection among Swedish prisoners in Stockholm County was 11.5%, which is high in comparison to the general population. Therefore, when aiming for the WHO goal of HCV elimination, prisons could suit as a platform for identification and treatment of HCV infection. There is a need to increase testing for blood-borne viruses and to improve vaccination coverage against HBV in Swedish prisons.
Sections du résumé
BACKGROUND
BACKGROUND
Identification and knowledge of settings with high prevalence of hepatitis C virus (HCV) infection is important when aiming for elimination of HCV. The primary aim of this study was to estimate the prevalence of viremic HCV infection among Swedish prisoners. Secondary aims were to estimate the prevalence of hepatitis B surface antigen (HBsAg), human immunodeficiency virus (HIV), and the proportion who have received hepatitis B virus (HBV) vaccination.
METHODS
METHODS
A cross-sectional study of all incarcerated persons (n = 667) at all prisons (n = 9) in Stockholm County was conducted. All prisoners are routinely offered opt-in screening for HCV antibodies (anti-HCV), HCV RNA, HBsAg, anti-HBs, anti-HBc and HIV Ag/Ab at prison in Sweden. Data on the results of these tests and the number of received HBV vaccine doses were collected from the prison medical records. The parameters of HCV RNA, anti-HCV, and occurrence of testing for HCV were analysed in multiple logistic regression models in relation to age, sex and prison security class.
RESULTS
RESULTS
The median age was 35 (IQR 26-44) years, and 93.4% were men. Seventy-one percent (n = 471) had been tested for anti-HCV, 70% (n = 465) for HBsAg and 71% (n = 471) for HIV. The prevalence of anti-HCV, HCV RNA, HBsAg and HIV Ag/Ab was 17.0, 11.5, 1.9, and 0.2%, respectively among tested persons. The proportion of prisoners who had received full HBV vaccination was 40.6% (n = 271) among all study subjects.
CONCLUSIONS
CONCLUSIONS
The prevalence of viremic HCV infection among Swedish prisoners in Stockholm County was 11.5%, which is high in comparison to the general population. Therefore, when aiming for the WHO goal of HCV elimination, prisons could suit as a platform for identification and treatment of HCV infection. There is a need to increase testing for blood-borne viruses and to improve vaccination coverage against HBV in Swedish prisons.
Identifiants
pubmed: 31706284
doi: 10.1186/s12879-019-4581-3
pii: 10.1186/s12879-019-4581-3
pmc: PMC6842501
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
Hepatitis C Antibodies
0
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
955Subventions
Organisme : Abbvie
ID : .
Organisme : BMS
ID : .
Organisme : Gilead
ID : .
Organisme : ICT Health Support
ID : .
Références
J Infect Public Health. 2013 Jun;6(3):186-95
pubmed: 23668463
Epidemiol Rev. 2018 Jun 1;40(1):105-120
pubmed: 29648594
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Commun Dis Public Health. 2004 Dec;7(4):306-11
pubmed: 15779795
BMC Infect Dis. 2018 Jul 21;18(1):339
pubmed: 30031373
Addiction. 2011 Nov;106(11):1978-88
pubmed: 21615585
Addiction. 2018 Jan;113(1):80-90
pubmed: 28710874
PeerJ. 2018 Feb 16;6:e4297
pubmed: 29472994
Am J Prev Med. 2019 Jan;56(1):8-16
pubmed: 30467088
Addict Sci Clin Pract. 2013 Dec 13;8:20
pubmed: 24330568
Hepatology. 2001 Oct;34(4 Pt 1):809-16
pubmed: 11584380
Eur J Public Health. 2016 Feb;26(1):122-8
pubmed: 26454876
MMWR Morb Mortal Wkly Rep. 2011 Jun 24;60(24):811-3
pubmed: 21697805
Harm Reduct J. 2018 May 11;15(1):25
pubmed: 29751763
J Viral Hepat. 2018 Dec;25(12):1406-1422
pubmed: 30187607
Int J Prison Health. 2016;12(1):3-16
pubmed: 26933988
Annu Rev Public Health. 2012 Apr;33:325-39
pubmed: 22224880
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
J Viral Hepat. 2014 May;21 Suppl 1:5-33
pubmed: 24713004
Lancet. 2016 Sep 10;388(10049):1089-1102
pubmed: 27427453
Infect Dis (Lond). 2017 Oct;49(10):728-736
pubmed: 28574295
Public Health Rep. 2017 Nov/Dec;132(6):617-621
pubmed: 29045799
Rev Soc Bras Med Trop. 2013 Jan-Feb;46(1):24-9
pubmed: 23563821
Hepatology. 2013 Oct;58(4):1215-24
pubmed: 23504650
PLoS One. 2017 Jan 6;12(1):e0169195
pubmed: 28060860
Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50
pubmed: 15508101
J Viral Hepat. 2019 Jan;26(1):101-108
pubmed: 30315691
Scand J Gastroenterol. 2000 Aug;35(8):861-5
pubmed: 10994626
Scand J Infect Dis. 2009;41(9):679-84
pubmed: 19521924
Hepatology. 2013 Nov;58(5):1598-609
pubmed: 23553643
Eur J Clin Microbiol Infect Dis. 2011 Jul;30(7):857-62
pubmed: 21274586
Clin Infect Dis. 2018 Jul 18;67(3):460-463
pubmed: 29538639
J Epidemiol Community Health. 2008 Apr;62(4):305-13
pubmed: 18339822
Am J Gastroenterol. 2008 May;103(5):1283-97; quiz 1298
pubmed: 18477352
BMC Public Health. 2013 Oct 20;13:981
pubmed: 24139133
World J Hepatol. 2015 Sep 28;7(21):2323-30
pubmed: 26413221
J Urban Health. 2012 Feb;89(1):108-16
pubmed: 22143408